293 related articles for article (PubMed ID: 31256282)
1. Emerging Role of Genomics and Cell-Free DNA in Breast Cancer.
Gerratana L; Davis AA; Shah AN; Lin C; Corvaja C; Cristofanilli M
Curr Treat Options Oncol; 2019 Jun; 20(8):68. PubMed ID: 31256282
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?
Buono G; Gerratana L; Bulfoni M; Provinciali N; Basile D; Giuliano M; Corvaja C; Arpino G; Del Mastro L; De Placido S; De Laurentiis M; Cristofanilli M; Puglisi F
Cancer Treat Rev; 2019 Feb; 73():73-83. PubMed ID: 30682661
[TBL] [Abstract][Full Text] [Related]
4. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of
Cayrefourcq L; Alix-Panabières C
Expert Rev Mol Diagn; 2020 Sep; 20(9):913-919. PubMed ID: 32856493
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells in breast cancer: applications in personalized medicine.
Lee JS; Magbanua MJM; Park JW
Breast Cancer Res Treat; 2016 Dec; 160(3):411-424. PubMed ID: 27761678
[TBL] [Abstract][Full Text] [Related]
7. Precision Medicine in Breast Cancer.
Odle TG
Radiol Technol; 2017 Mar; 88(4):401M-421M. PubMed ID: 28298516
[TBL] [Abstract][Full Text] [Related]
8. Preanalytical Variables for the Genomic Assessment of the Cellular and Acellular Fractions of the Liquid Biopsy in a Cohort of Breast Cancer Patients.
Shishido SN; Welter L; Rodriguez-Lee M; Kolatkar A; Xu L; Ruiz C; Gerdtsson AS; Restrepo-Vassalli S; Carlsson A; Larsen J; Greenspan EJ; Hwang ES; Waitman KR; Nieva J; Bethel K; Hicks J; Kuhn P
J Mol Diagn; 2020 Mar; 22(3):319-337. PubMed ID: 31978562
[TBL] [Abstract][Full Text] [Related]
9. Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine.
Kerachian MA; Poudineh A; Thiery JP
Crit Rev Oncol Hematol; 2019 Dec; 144():102827. PubMed ID: 31715326
[TBL] [Abstract][Full Text] [Related]
10. Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer.
Gianni C; Palleschi M; Merloni F; Di Menna G; Sirico M; Sarti S; Virga A; Ulivi P; Cecconetto L; Mariotti M; De Giorgi U
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430675
[TBL] [Abstract][Full Text] [Related]
11. Advances in Tumor Sampling and Sequencing in Breast Cancer and their Application in Precision Diagnostics and Therapeutics.
Lee AC; Lee HB; Yeom H; Song SW; Kim SD; Choi A; Lee S; Lee Y; Han W; Kwon S
Adv Exp Med Biol; 2021; 1187():215-244. PubMed ID: 33983581
[TBL] [Abstract][Full Text] [Related]
12. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
13. Genetic heterogeneity in breast cancer: the road to personalized medicine?
Baird RD; Caldas C
BMC Med; 2013 Jun; 11():151. PubMed ID: 23800221
[TBL] [Abstract][Full Text] [Related]
14. Genomic and transcriptional heterogeneity-based precision in personalized treatment for breast cancer.
Antoniou P; Ziogas DE; Vlachioti A; Lykoudis EG; Mitsis M; Roukos DH
Per Med; 2019 Sep; 16(5):361-364. PubMed ID: 31507233
[No Abstract] [Full Text] [Related]
15. Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment.
Pinker K; Chin J; Melsaether AN; Morris EA; Moy L
Radiology; 2018 Jun; 287(3):732-747. PubMed ID: 29782246
[TBL] [Abstract][Full Text] [Related]
16. What to look for in cell-free DNA from breast cancer patients.
Bronte G; Ravaioli S; Bravaccini S
Breast Cancer Res Treat; 2018 Jul; 170(1):199-200. PubMed ID: 29480448
[No Abstract] [Full Text] [Related]
17. Circulating Tumor DNA: A Step into the Future of Cancer Management.
Fernandes Marques J; Pereira Reis J; Fernandes G; Hespanhol V; Machado JC; Costa JL
Acta Cytol; 2019; 63(6):456-465. PubMed ID: 30852572
[TBL] [Abstract][Full Text] [Related]
18. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB).
Rolfo C; Cardona AF; Cristofanilli M; Paz-Ares L; Diaz Mochon JJ; Duran I; Raez LE; Russo A; Lorente JA; Malapelle U; Gil-Bazo I; Jantus-Lewintre E; Pauwels P; Mok T; Serrano MJ;
Crit Rev Oncol Hematol; 2020 Jul; 151():102978. PubMed ID: 32428812
[TBL] [Abstract][Full Text] [Related]
19. Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer.
Kratz J; Burkard M; O'Meara T; Pusztai L; Veitch Z; Bedard PL
Am Soc Clin Oncol Educ Book; 2018 May; 38():56-64. PubMed ID: 30231387
[TBL] [Abstract][Full Text] [Related]
20. Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC).
Gerratana L; Zhang Q; Shah AN; Davis AA; Zhang Y; Wehbe F; Qiang W; Flaum L; Finkelman BS; Gradishar WJ; Platanias LC; Behdad A; Cristofanilli M
Crit Rev Oncol Hematol; 2020 Jan; 145():102856. PubMed ID: 31884205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
